HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Up 158.1% in March

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 110,641 shares, a growth of 158.1% from the March 15th total of 42,868 shares. Currently, 5.5% of the company’s shares are sold short. Based on an average daily trading volume, of 41,337,246 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, HCW Biologics presently has an average rating of “Hold” and a consensus price target of $35.00.

HCW Biologics Stock Up 8.1%

NASDAQ:HCWB opened at $0.36 on Friday. HCW Biologics has a 12-month low of $0.25 and a 12-month high of $17.80. The firm has a market capitalization of $1.28 million, a P/E ratio of -0.04 and a beta of 0.90. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $1.84.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($2.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($1.79). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $7.01 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new position in HCW Biologics Inc. (NASDAQ:HCWB) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.96% of the company’s stock.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.